Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more
Upstream Bio, Inc. (UPB) - Total Liabilities
Latest total liabilities as of September 2025: $12.61 Million USD
Based on the latest financial reports, Upstream Bio, Inc. (UPB) has total liabilities worth $12.61 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Upstream Bio, Inc. - Total Liabilities Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Upstream Bio, Inc. Competitors by Total Liabilities
The table below lists competitors of Upstream Bio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Village Farms International Inc
NASDAQ:VFF
|
USA | $113.02 Million |
|
Matrix Service Co
NASDAQ:MTRX
|
USA | $512.64 Million |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
China | CN¥484.37 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩257.46 Billion |
|
Jinan High tech Development Co Ltd
SHG:600807
|
China | CN¥2.16 Billion |
|
Turners Automotive Group Ltd
AU:TRA
|
Australia | AU$659.14 Million |
|
Genomictree Inc.
KQ:228760
|
Korea | ₩6.94 Billion |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
Sweden | Skr997.70 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down Upstream Bio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Upstream Bio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Upstream Bio, Inc. (2022–2024)
The table below shows the annual total liabilities of Upstream Bio, Inc. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.87 Million | -95.06% |
| 2023-12-31 | $240.32 Million | +92.83% |
| 2022-12-31 | $124.63 Million | -- |